Screener
Xeris Biopharma Holdings, Inc. XERS Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s other non-current liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported other non-current liabilities of $12.72M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s other non-current liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s other non-current liabilities increased by 64.1% year-over-year, from $7.75M to $12.72M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other non-current liabilities?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s other non-current liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $3.53M to $8.4M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Xeris Biopharma Holdings, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude